- Home
- SITC vs AKBA Comparison
SITC vs AKBA Comparison
Compare SITC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- AKBA
- Stock Information
- Founded
- SITC 1965
- AKBA 2007
- Country
- SITC United States
- AKBA United States
- Employees
- SITC N/A
- AKBA N/A
- Industry
- SITC Real Estate Investment Trusts
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- AKBA Health Care
- Exchange
- SITC Nasdaq
- AKBA Nasdaq
- Market Cap
- SITC 603.6M
- AKBA 559.0M
- IPO Year
- SITC 1993
- AKBA 2014
- Fundamental
- Price
- SITC $12.05
- AKBA $2.55
- Analyst Decision
- SITC Hold
- AKBA Strong Buy
- Analyst Count
- SITC 8
- AKBA 4
- Target Price
- SITC $35.25
- AKBA $6.63
- AVG Volume (30 Days)
- SITC 601.4K
- AKBA 3.7M
- Earning Date
- SITC 05-07-2025
- AKBA 05-08-2025
- Dividend Yield
- SITC 4.33%
- AKBA N/A
- EPS Growth
- SITC 151.39
- AKBA N/A
- EPS
- SITC 10.33
- AKBA N/A
- Revenue
- SITC $227,525,000.00
- AKBA $184,909,000.00
- Revenue This Year
- SITC N/A
- AKBA $22.50
- Revenue Next Year
- SITC $13.35
- AKBA $43.23
- P/E Ratio
- SITC $1.16
- AKBA N/A
- Revenue Growth
- SITC N/A
- AKBA N/A
- 52 Week Low
- SITC $10.46
- AKBA $0.80
- 52 Week High
- SITC $64.44
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- SITC 49.86
- AKBA 65.48
- Support Level
- SITC $11.71
- AKBA $2.25
- Resistance Level
- SITC $12.23
- AKBA $2.90
- Average True Range (ATR)
- SITC 0.26
- AKBA 0.14
- MACD
- SITC 0.08
- AKBA 0.03
- Stochastic Oscillator
- SITC 74.47
- AKBA 58.33
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.